<DOC>
	<DOCNO>NCT02412462</DOCNO>
	<brief_summary>This Phase 1 clinical study investigate safety , pharmacokinetics pharmacodynamics AB-16B5 patient advance solid malignancy . AB-16B5 humanize monoclonal antibody inhibit activity secrete form clusterin ( sCLU ) , potent inducer epithelial-to-mesenchymal transition ( EMT ) . Eligible subject disease refractory prior therapy unlikely benefit know therapy .</brief_summary>
	<brief_title>Phase I Dose Escalation Study AB-16B5 Subjects With Advanced Solid Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Subjects histologically cytologically confirm advanced solid malignancy refractory prior therapy unlikely benefit know therapy . Subjects may measurable nonmeasurable evaluable disease . Subjects must Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 estimate life expectancy least 12 week . Subjects must ≥ 18 year old . Male , female subject postmenopausal ( amenorrheic least 12 month ) , surgically biologically sterile . Females childbearing potential negative serum pregnancy test prior enter study use adequate form contraception duration study , include 30 day last treatment . Males avoid father child course study , adequate method contraception use male female subject . Subjects partner reproductive potential must use effective contraceptive method subject study treatment 30 day last treatment . Subjects must adequate organ immune function indicate follow laboratory value : ANC ≥ 1.5 X 109/L Platelets &gt; 100 X 109/L Hemoglobin ≥ 90 g/L Serum creatinine ≤ 132 µmol/L Total Bilirubin ≤ 1.5 X ULN AST ( SGOT ) ALT ( SGPT ) ≤ 3 X ULN* ; 5 X ULN* ( hepatic metastasis present ) ULN : Institution 's upper limit normal Subjects enrol standard dose escalation portion study must tumor lesion amenable biopsy contraindication biopsy . Subjects must understand able willing likely fully comply study procedure , include schedule followup , restriction . Subjects must give write personally sign date informed consent participate study , accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guidelines , complete study related procedure . Subjects medical , social , psychosocial factor , opinion Investigator , could impact safety compliance study procedure . Prior cancer therapy include surgery , radiotherapy , chemotherapy , hormonal biological therapy within 3 week prior study treatment . Uncontrolled brain metastasis . Uncontrolled infection . Clinically significant ECG abnormality . Known hypersensitivity Grade &gt; 2 previous monoclonal antibody therapy . History alcohol substance abuse within last year . Use another investigational agent clinical trial within last 4 week prior study treatment . Female subject pregnant lactating , include female positive pregnancy test screening must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Clusterin</keyword>
	<keyword>Epithelial-to-Mesenchymal Transition ( EMT )</keyword>
	<keyword>Circulating Tumor Cells ( CTC )</keyword>
	<keyword>EMT Stem Cell Biomarkers</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>